TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05608785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI315
Description: IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
Study: NCT05451407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection
Description: Humanized IgG4 mab targeting TIM-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab injection
Description: Monoclonal antibody against Programmed death factor receptor 1
Study: NCT05608785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 is a high-affinity humanized monoclonal antibody targeting Claudin 18.2 with enhanced antibody-dependent cytotoxic (ADCC) and complement-dependent cytotoxic (CDC) activity, showing potent antitumor activity in xenograft assays.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anrotinib
Description: Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
Study: NCT05559619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: 1000 mg of natural calcium carbonate once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: 1000 mg of natural calcium carbonate once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 1000 IU vitamin D3 once daily for 12 weeks
Study: NCT06649630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.
Study: NCT05559619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 1000 IU vitamin D3 once daily for 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser acupuncture therapy
Description: The patient was in crock lying for stimulation of acupoints in abdomen and lower limbs then asked to be in side lying for stimulation of acupoints in the back. After disinfection of the skin and careful localization of the acupoints, low level laser therapy (LLLT) (model: Lis 1050, SN: EM 13481014, manufactured by EME srl, Italy) was applied bilaterally on Dazhu (BL 11), Ganshu(BL 18), Pishu (BL20), Shenshu (BL23), Zusanli (ST 36), Sanyinjiao (Sp6), Jingmen(GB25), Yanglingquan (GB34) andXuanzhong (GB39) acupoints, while it was applied in the midline on Guanyuan (CV4) andMingmen (GV4) acupoints. Each acupoint was irradiated for 60 sec, with total duration of 20 min, wave length of 905 nm, average radiant power output of 12 mW, energy density of 2 J/cm2, pulse radiation of 200 ms and pulse frequency of 5000 Hz
Study: NCT06649630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.
Study: NCT04646616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community popular opinion leader (POL) based intervention
Description: A community popular opinion leader (POL) based intervention to promote measures to reduce COVID-19 risk, transmission, access to testing and treatment, reduction of the impact of COVID-19, and addressing the Substance Abuse, Violence, HIV/AIDS, and MEntal health (SAVAME) syndemic in the community. POLs will interact within their networks counseling regarding COVID-19 and SAVAME factors. The POLs will refer individuals to appropriate community services. POLs will record basic sociodemographic characteristics of all community contacts, the issue addressed, and their response to it. The first 300 community contacts will be invited to complete a baseline and 3-month follow up surveys (via internet or phone). The content of the surveys includes: 1) COVID-19 related questions (knowledge, impact, symptoms, risk factors, access to testing and care, acceptability contact tracing, vaccine) 2) Biological risk factors, 3) Social determinants of health, 4) SAVAME outcomes and access to services.
Study: NCT05210920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nail polish application
Description: After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nail polish application
Description: After application of nail polish as described, participants will have bacterial swabs collected from the under the fingernail and from the nail bed of the three assigned fingers on their dominant hand, both before and after scrubbing with a chlorhexidine surgical scrubbing brush.
Study: NCT06265220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: NK Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 antibody therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Anti-CD20 antibody therapy
Study: NCT06050590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroGlove
Description: Study participant with PTSD will undergo daily at home treatment using the NeuroGlove.
Study: NCT05375513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PMI@Home
Description: Personalized multidomain interventional program by combining tailored lifestyle interventions that targets 5 domains: physical activity, cognition, diet, sleep, and vascular risk factors. These interventions are tailored based on participants' baseline profile and progress in intensity following the principles of personalized medicine. All aspects of the PMI@home will be delivered remotely, at participants' homes, using a digital platform with scheduled bi-weekly 1-to1 coaching sessions. Delivery of interventions and assessments are centralized with 5 trained staff at the sponsor site (London) to assure logistics, standardization, and quality control.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brain Health Pro
Description: Online Modules:~* Motivation, Self-Efficacy, Positive Health, Environment and Genetic risk~* Physical Activity~* Cognitively Stimulating Activities~* Diet~* Sleep~* Social and Psychological Health~* Vascular health~* Vision and Hearing~* Lifestyle Risk Impact Surveys~* Goal Setting
Study: NCT05100875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills and Emotion Regulation Training SSERT
Description: The SSERT intervention will broadly consist of the following 10 modules: (1) Introducing the Participant to Treatment; (2-3) Emotional Awareness and Recognition; (4-5) Emotion Regulation and Understanding Emotions in the Context of Psychotic Experiences; (6) Living an Emotionally Engaged Life; (7) Understanding Relationship Patterns in the Context of Psychosis; (8) Changing Undesirable Relationship Patterns; (9) Learning to have agency in Relationships; and (10) Flexibility in Relationships and Transitioning to Trauma-Focused Therapy.
Study: NCT06721949

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule is visually identical to the taurine capsule.
Study: NCT06721117

Intervention type: OTHER
Intervention: Grip strength assessment
Description: Jamar hand dynamometer, recommended by the American Hand Therapists Association and accepted as the gold standard in many studies due to its high validity and reliability, will be used to measure hand grip strength. Pinchmeter (Baseline Mechanical Pinch Gauge) will be used to measure fine grip strength. Hand grip and finger grip strength measurements will be made in the recommended standard position of sitting, shoulder adduction and neutral rotation, elbow 90 degrees flexed, forearm in mid-rotation and supported, wrist in neutral. In the test procedure, 3 measurements will be taken for hand grip and finger grip strengths with one-minute intervals between each measurement and the averages will be recorded.

Intervention type: OTHER
Intervention: Forearm muscle strength assessment
Description: Wrist isometric muscle strength assessment will be performed with a handheld dynamometer (Lafayette Instrument Company, Lafayette, Indiana, USA). Patients will be placed in the supine, prone and sitting positions using the positions required for the fine muscle test method defined by Lovett and will be performed without compensatory movements. Wrist flexor and extensor muscles will be assessed. The values obtained with isometric contraction will be recorded in kg. Muscle strength measurements will be assessed bilaterally, in three repetitions for 5 seconds. The average value of the three repetition results will be recorded.
Study: NCT06257784

Intervention type: PROCEDURE
Intervention: Oxygen Therapy
Description: Patients who have SpO2 \< 92% on room air will undergo oxygen therapy (nasal cannula or Venturi-mask).

Intervention type: PROCEDURE
Intervention: Non-Invasive Ventilation (NIV)
Description: Patients with P/F \< 250 or Ph \< 7,35 with PCO2 \> 50 mmHg will undergo Non-Invasive Ventilation (NIV) (high flow nasal cannula or CPAP).

Intervention type: PROCEDURE
Intervention: Invasive Ventilation
Description: Patients with P/F \< 150 associated to dyspnea at rest (moderate to severe, shortness of breath and/ or tachypnea (\>24 breaths/min) despite NIV for at least 2 hours or patients with Ph \< 7,2 with PCO2 \> 60 mmHg despite NIV for at least 2 hours will undergo invasive ventilation (intubation).
Study: NCT04424121

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CCTA
Description: Coronary Computed Tomography Angiography
Study: NCT06504017

Intervention type: PROCEDURE
Group type: OTHER
Intervention: COG-TB: Cognitive Fusion guided prostate targeted Biopsy
Description: Cognitive Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FUS-TB: MRI-TRUS Fusion guided prostate targeted Biopsy
Description: MRI-TRUS Fusion guided targeted Biopsy 4 cores under cognitive fusion ultrasound
Study: NCT06532123

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continence muscles resistance device
Description: The c-RED consists of a noncompliant cylindrical balloon (intra-anal balloon) that is connected to a small compliant balloon (external balloon) by a 2 mm diameter tube and a stopcock to allow for air to be filled and sealed in the system. The system is prefilled with air to determine the amount of air needed for a given internal pressure, or desired resistance of the intra-anal balloon. This is determined using a sphygmomanometer gauge in a sealed system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continence muscles resistance device
Description: The c-RED consists of a noncompliant cylindrical balloon (intra-anal balloon) that is connected to a small compliant balloon (external balloon) by a 2 mm diameter tube and a stopcock to allow for air to be filled and sealed in the system. The system is prefilled with air to determine the amount of air needed for a given internal pressure, or desired resistance of the intra-anal balloon. This is determined using a sphygmomanometer gauge in a sealed system.
Study: NCT05351008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy
Description: A physicaltheapy approach combining cognitive techniques, func-tional movement training, functional integration and Lifestyle Changes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program:
Description: Core strengthening program
Study: NCT06216951

Intervention type: PROCEDURE
Intervention: Vital Pulpotomy
Description: Vital pulpotomy involves the removal of the coronal pulp, while MTA is used to seal the root orifices. It is clear that vital pulp treatments for symptomatic pulpitis are a more reliable, cost-effective, and generally easier option than root canal treatment (RCT) once the mineral trioxide aggregate (MTA) is introduced in dentistry. In vital pulpotomy, as opposed to RCT, tooth healing and symptoms are diminished while the vitality of the tooth is maintained. Furthermore, vital pulpotomy is a significantly more practical and economical treatment alternative than RCT.
Study: NCT06078735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular closure with LockeT device
Description: For subjects that are assigned to the LockeT device arm, the healthcare professional will place the LockeT with suture above the wound to achieve compression instead of manually holding pressure on the sutures. After hemostasis is achieved and prior to ambulation the LockeT will be removed followed by suture removal.
Study: NCT05126888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCI-110
Description: SCI-110 - a softgel capsule containing Dronabinol and Palmitoylethanolamide (PEA) in the following doses: 2.5mg Dronabinol+400mg PEA, 5mg Dronabinol+400mg PEA and 10mg Dronabinol+400mg. Maximum dose 20mg Dronabinol and 800mg PEA a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill that matches in taste, odour and appearance to SCI-110 active pills
Study: NCT05645627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112
Description: IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo /IBI112
Description: placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112
Description: IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
Study: NCT04719910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual exposure to taped food preparation
Description: Patients in the study group can watch the preparation of the the type of food she prefers to eat normally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Visual exposure to topics not related to food
Description: Patients in the placebo group can choose a video that is relaxing but not related to food.
Study: NCT06649630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0442-0344 A
Description: SAD: NNC0442-0344 A will be administered intravenously.~MAD: NNC0442-0344 A will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAD: Placebo will be administered intravenously.~MAD: Placebo will be administered orally.
Study: NCT06650644

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Lactococcus lactis KD10
Description: * Food Name: Placebo of Lactococcus lactis KD10~* Ingredients: Natural pigment enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Dosage period and route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactococcus lactis KD10 (health food)
Description: * Food Name: Lactococcus lactis KD10 (health food)~* Ingredients: Freeze-dried Lactococcus lactis enteric-coated granules preparation~* Appearance and Formulation: Granules/Powder~* Dosage/Amount: 1 pack once a day~* Administration Period and Route: Oral intake of 1 pack once a day for 12 weeks 30 minutes after meals
Study: NCT06652386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Group
Description: * Nursing-led lactation support via secure video conferencing platforms (e.g., Zoom for Healthcare).~* Scheduled sessions at postpartum days 1, 3, 7, and 14.~* Additional support available upon request.
Study: NCT06594289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In laparoscopic hepatectomy, the subhepatic inferior vena cava was restricted and the patient was given non-restricted intraoperative fluid intake
Description: The specific steps of IVC blocking were performed by the principal physician under laparoscopic operation: slightly incision of the posterior peritoneum on both sides of the inferior vena cava above the level of the renal vein. The blood vessel blocking band is passed behind the inferior vena cava on the left or right side of the inferior vena cava. According to the intraoperative situation, the blocking band (flow limiting blocking/incomplete blocking of subhepatic inferior vena cava) was tightened to control the bleeding from hepatic vein on the liver section. Patients in this group did not use vasoactive drugs/underuse means to control CVP, so they need to strictly communicate with the anesthesiologist, and take the fluid intake based on the physiological requirements and fluid loss of individual patients (cancel the restriction of fluid intake).
Study: NCT05260307

Intervention type: OTHER
Group type: OTHER
Intervention: hearing aid condition
Description: The intervention will be a hearing aid or a modification to the sound stimulus that simulates a hearing aid configuration, style, or processing strategy.
Study: NCT05803876

Intervention type: OTHER
Intervention: Diagnostic test - monitoring
Description: Continuous measurement of blood velocity in the middle cerebral artery by transcranial pulsed Doppler (TCD) Atys Medical TCD-X®. The probe attachment system on the patient's head looks like a pair of glasses; it is light and comfortable. The orientation of the robotic probe is automatically readjusted to ensure stable recording quality over time. (recorded on Data Warehouse Connect).~For all patients Vm in (cm/s) will be collected during the adjustment of the mean arterial pressure level between 90% and 70% of the baseline value, without ever going below 60 mmHg for the patients at low risk and 80 mmHg for the patients at high cardiovascular risk.
Study: NCT06510114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone(daily scheme)
Description: 0.5 g methylprednisolone i.v. daily for 5 consecutive days, followed by oral prednisone for 6 months. Oral prednisone started at 40 mg/day for 4 weeks and then the dose was tapered by 5 mg/day every 2-4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone(weekly scheme)
Description: 0.5 g methylprednisolone i.v. weekly for 6 weeks and then the dose was tapered by 0.25 g/week over the following 6 weeks.
Study: NCT06229574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: The breastfeeding software developed will be applied in this group.
Study: NCT04988685

Intervention type: DEVICE
Intervention: Sirolimus Eluting Balloon
Description: PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon
Study: NCT06440772

Intervention type: DRUG
Intervention: Ringer's Lactate Crystalloid Solutions
Description: 7 ml/kg ml of Ringer's Lactate is given in 10 min amongst initially tolerant fluid responders.